Close Menu

Silence

Rosetta Genomics said that its chief commercialization officer would resign as the company settles into its latest change in corporate direction. But the company is not the only player in the RNAi/microRNA space to experience changes to its management lineup.

People in the News: May 6, 2010

Premium

Douglas Fambrough, Jorg Kaufmann

An update on the RNAi drug pipelines for Alnylam, Calando, Pfizer, Quark, Silence Therapeutics, Sylentis, Tekmira, TransDerm, and Zabecor.

The deal, which is independent of another arrangement under which Silence is developing siRNA drugs against AstraZeneca-specified targets, has been extended for one year.

Silence said that as a result of the consolidation, it has laid off about 20 staffers, primarily in research and development.

Max Herrmann, John Maraganore

Under the expanded deal, Silence will demonstrate functional delivery of siRNAs against new targets selected by Dainippon.

Although RNAi can be used to knock down virtually any gene of interest, companies working in the space have taken a decidedly measured approach in building their internal pipelines, maintaining a relatively small number of drug-development programs.

The target, PKN-3, is a protein kinase C-related molecule associated with the growth of cancer cells, as well as metastasis formation, and is the target for the company's phase I siRNA-based solid tumor drug Atu-027.

The patent, DE 10066235, was granted in January 2008, and covers methods, uses, and medicaments of siRNAs, with a length between 15 and 49 nucleotides, expressed through a vector, according to Alnylam.

Pages

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.